Prempro WHI Implications For Future HRT Trials To Be Discussed By Subcmte.
Executive Summary
Implications of the Women's Health Initiative study results for future clinical trials of hormone replacement therapy will be discussed by an ad hoc subcommittee of FDA's Reproductive Health Drugs Advisory Committee on Nov. 12-13
You may also be interested in...
FDA Women’s Health Initiative Advisory Committee Meeting Postponed
The Nov. 12-13 meeting of the Women's Health Initiative Subcommittee of FDA's Reproductive Health Drugs Advisory Committee has been postponed
FDA Women’s Health Initiative Advisory Committee Meeting Postponed
The Nov. 12-13 meeting of the Women's Health Initiative Subcommittee of FDA's Reproductive Health Drugs Advisory Committee has been postponed
FDA Reproductive Cmte. Membership Reflects “Broken Process” – Crawford
FDA's difficulty in staffing the Reproductive Health Drugs Advisory Committee is a result of a "broken process," Acting Commissioner Lester Crawford told a Women in Government Relations luncheon in Washington, D.C. Oct. 11